David Jayne
University of Cambridge, Addenbrooke's Hospital
Research areas: Medicine · Rheumatology · Vasculitis and related conditions · Systemic Lupus Erythematosus Research · Renal Diseases and Glomerulopathies
0000-0002-1712-0637
About
David Jayne is Professor of Clinical Autoimmunity at the University of Cambridge, UK, and Director of the Vasculitis and Lupus service at Addenbrookes Hospital Cambridge. He trained at the Universities of Cambridge and London, and in nephrology at Harvard Medical School, Boston, USA. He was a research fellow at Imperial College London and the University of Cambridge and was appointed Senior Lecturer in Nephrology at St George’s Hospital, London in 1995.
He is a co-founder and the current President of the European Vasculitis Society and his research focus has been ANCA vasculitis and lupus nephritis, having led a sequence of International randomised controlled trials over the last 25 years. His research group conducts first into disease trials of newer immunosuppressives and biologics in vasculitis and lupus. He has published over 500 peer reviewed papers and has contributed to numerous guideline statements. His work with industry has contributed to the approval of avacopan for ANCA associated vasculitis and voclosporin for lupus nephritis. The clinical service in Cambridge cares for over 2000 patients with complex multi-system autoimmunity and receives tertiary referrals from throughout the UK and beyond. In 2021 he was awarded the ERA-EDTA prize for outstanding contributions to nephrology.
Employment
-
University of Cambridge Professor2013 - Present
-
Addenbrookes Hospital Honorary Consultant2001 - Present
Education
Education history is unavailable.
Projects & Funding
-
MICA: A randomised, double blind, controlled mechanistic study of obinutuzumab versus rituximab in ANCA-associated vasculitis (ObiVas) Medical Research Council2022 - 2027
-
Transcriptomic deconvolution to dissect the immunological mechanism of B cell depletion therapy in ANCA associated vasculitis. National Institute for Health and Care Research2022 - 2023
-
EPIDEMIOLOGIC STUDIES ON SYSTEMIC VASCULITIS: EMPHASIS ON AETIOLOGY, COMORBIDITIES AND HEALTH ECONOMIC ASPECTS. Swedish Research Council2020 - 2022
-
The significance of Staphylococcus aureus carriage and granulomatosis with polyangiitis: Pathophysiological alterations unravelled. Versus Arthritis2020 - 2025
-
HAVEN: Hydroxychloroquine in ANCA Vasculitis Evaluation, a Phase II Multicentre, Randomised, Double Blind, Placebo Controlled Trial Medical Research Council2019 - 2025
-
Biologics in refractory vasculitis (BIOVAS): A pragmatic randomised double-blind placebo-controlled modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children NIHR Evaluation Trials and Studies Coordinating Centre2019 - 2025
-
A mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis Medical Research Council2017 - 2023
-
MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches (MASTERPLANS) Medical Research Council2015 - 2021
-
Plasma exchange and glucocorticoids in anti-neutrophil cytoplasm antibody associated systemic vasculitis: a randomised controlled trial (PEXIVAS Australia) National Health and Medical Research Council2015 - 2018
-
A BIOMARKER AND PATHWAY DISCOVERY PROGRAMME IN INFLAMMATORY DISEASE Medical Research Council2014 - 2020
-
A randomised controlled trial comparing rituximab to standard immunosuppression as maintenance therapy in ANCA associated vasculitis. Versus Arthritis2011 - 2018
-
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomized controlled trial Canadian Institutes of Health Research2010 - 2017
-
Plasma Exchange and Glucocorticoids in ANCA Associated Vasculitis: A Randomised Controlled Trial (PEXIVAS Australia) National Health and Medical Research Council2010 - 2015
-
Plasma exchange and glucocorticoids in anti-neutrophil cytoplasm antibody associated systemic vasculitis: a randomized controlled trial. PEXIVAS NIHR Evaluation Trials and Studies Coordinating Centre2009 - 2018
-
A randomized study on the effects of long-term, low-dose corticosteroids compared to placebo on flare rates during maintenance therapy for proliferative lupus nephritis. Canadian Institutes of Health Research2006 - 2009
Publications (506)
- Long-term comparative outcomes of rituximab and belimumab in lupus patients Save
- Plasma Exchange for Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Reframing the Evidence Through Bayesian Analysis Save
- Large Vessel Vasculitis Revisited: Mechanistic Insights and Advances in Diagnosis and Management Save
- Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis Save
- Reply Save
- Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab Save
- Evaluation of the Long-Term Safety of Avacopan in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in the Real World (AvacoStar): Protocol for a Noninterventional Prospective Cohort Study Save
- Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand? Save
- The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis Save
- Clinician views concerning the prevalence and impact of granulomas on the diagnosis, management, and outcomes of ANCA-associated vasculitis Save
- Longitudinal Trajectories of Kidney Function in Patients with Severe ANCA-Associated Vasculitis Save
- Addressing clinical challenges in ANCA-associated vasculitis with real-world evidence Save
- Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis Save
- Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies Save
- Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide Save
- Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial Save
- Update on therapeutic approaches in ANCA-associated vasculitis Save
- Evaluation of the long-term safety of avacopan in ANCA-associated vasculitis: Design of the real-world AvacoStar study (Preprint) Save
- Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab Save
- Reply Save